BioWorld

Aug. 2, 2004

View Archived Issues

Gilead's HIV Franchise Strong; Earnings Top Analyst Estimates

Gilead Sciences Inc. walloped forecasts by posting second-quarter net income that was up 11 percent, thanks to the briskly selling HIV treatment Viread and the hepatitis B therapy Hepsera. (BioWorld Today) Read More

CV Therapeutics Gets Second Ranexa SPA For Angina, ACS

Read More

Already Being Tested Against Cancer, Bryostatin Showing Promise In Alzheimer's Fight

Read More

NAS Report On GM Foods Welcomed By Industry, BIO

Read More

Other News To Note

Read More